An estimated 70 million people globally suffer a traumatic brain injury (TBI) each year. Concussion is a difficult diagnoses, not to mention the associated high cost of diagnosis and the possibility of exposure to radiation in CT.
itremor aims to provide a cutting-edge technology and associated medical device for the evaluation of brain health in TBI and sports concussion. There are currently limited options to accurately and quickly diagnose concussion using a non-invasive medical device on a sports pitch, in an emergency department, in the military or in the home. Moreover, the diagnosis is often subjective, using mainly cognitive testing. In many cases CT scans and MRIs are used ineffectively to detect mild concussion (approx. 80% of all concussions) with the net result being that an estimated 90% of these scans are negative.
The itremor solution aims to provide a comprehensive result as to whether a player or patient has a concussion or not. The medical device aims to diagnose a concussion using a mix of technologies and algorithms to detect certain aspects of brain function at the time of the concussion or shortly thereafter. The device aims to provide a quick diagnosis, is non-invasive, simple to use, durable and a reasonable cost versus existing diagnostic solutions.
Our team is a blend of experienced leaders in business, biomedical engineering, electronic engineering and cognitive neuroscience. The team is led by David van Zuydam (CEO) who has worked for global blue-chip companies as well as small to mid-size business (SMB) at CXO level. The bio-engineering team is driven by two PHD doctorates operating out of St James’s Hospital and supported by another PHD doctorate covering clinical trials and the regulatory requirements.
The next key phase of our journey is to complete our initial trials, which are currently underway, appoint design and manufacture partners, and close our first round of funding by the end of 2018.